NFSG Corp Buys 1,497 Shares of Cencora, Inc. $COR

NFSG Corp lifted its stake in Cencora, Inc. (NYSE:COR) by 14,970.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,507 shares of the company’s stock after buying an additional 1,497 shares during the quarter. NFSG Corp’s holdings in Cencora were worth $452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Steph & Co. boosted its stake in shares of Cencora by 23.5% during the 1st quarter. Steph & Co. now owns 168 shares of the company’s stock valued at $53,000 after purchasing an additional 32 shares in the last quarter. Cornerstone Wealth Group LLC raised its stake in Cencora by 1.6% in the first quarter. Cornerstone Wealth Group LLC now owns 2,434 shares of the company’s stock worth $760,000 after buying an additional 38 shares in the last quarter. OLD National Bancorp IN raised its stake in Cencora by 0.4% in the first quarter. OLD National Bancorp IN now owns 9,964 shares of the company’s stock worth $3,130,000 after buying an additional 40 shares in the last quarter. Staley Capital Advisers Inc. raised its stake in Cencora by 0.7% in the first quarter. Staley Capital Advisers Inc. now owns 6,127 shares of the company’s stock worth $1,925,000 after buying an additional 40 shares in the last quarter. Finally, Elmwood Wealth Management Inc. lifted its stake in shares of Cencora by 0.9% in the 2nd quarter. Elmwood Wealth Management Inc. now owns 4,314 shares of the company’s stock valued at $1,221,000 after purchasing an additional 40 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of a number of analyst reports. Wells Fargo & Company boosted their price target on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. Robert W. Baird lifted their price target on Cencora from $370.00 to $373.00 and gave the stock an “outperform” rating in a research report on Monday, October 12th. Argus dropped their price target on shares of Cencora to $340.00 and set a “buy” rating on the stock in a research note on Tuesday, June 23rd. Weiss Ratings upgraded shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. Finally, Citigroup reissued a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $363.81.

Cencora Stock Down 0.3%

COR traded down $0.87 during trading on Friday, hitting $340.54. 1,978,868 shares of the company’s stock traded hands, compared to its average volume of 1,282,490. The company’s 50 day simple moving average is $320.38 and its two-hundred day simple moving average is $303.34. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market capitalization of $64.99 billion, a price-to-earnings ratio of 25.30, a PEG ratio of 1.75 and a beta of 0.58.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. During the same quarter last year, the company earned $4.00 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Analysts predict that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 17.83%.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.